Comparison 3. Prostatic arterial embolization (PAE) versus sham (short term).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Urologic symptom scores	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1.1 RCTs	1	80	Mean Difference (IV, Random, 95% CI)	‐12.07 [‐15.45, ‐8.69]
3.2 Quality of life	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.2.1 RCTs	1	80	Mean Difference (IV, Random, 95% CI)	‐1.97 [‐2.48, ‐1.46]
3.3 Major adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.3.1 RCTs	1	80	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
3.4 Retreatment	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.4.1 RCTs	1	80	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
3.5 Ejaculatory disorder	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.5.1 RCTs	1	80	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
3.6 Minor adverse events	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.6.1 RCTs	1	80	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.58, 1.99]
3.7 Acute urinary retention	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.7.1 RCTs	1	80	Risk Ratio (M‐H, Random, 95% CI)	Not estimable